Uptake of Re-188-beta-naphthyl-peptide in cervical carcinoma tumours in athymic mice

Citation
Ca. De Murphy et al., Uptake of Re-188-beta-naphthyl-peptide in cervical carcinoma tumours in athymic mice, NUCL MED BI, 28(3), 2001, pp. 319-326
Citations number
17
Categorie Soggetti
Medical Research Diagnosis & Treatment
Journal title
NUCLEAR MEDICINE AND BIOLOGY
ISSN journal
09698051 → ACNP
Volume
28
Issue
3
Year of publication
2001
Pages
319 - 326
Database
ISI
SICI code
0969-8051(200104)28:3<319:UORICC>2.0.ZU;2-I
Abstract
Radiolabelled somatostatin analogues have been used in diagnostic and thera peutic nuclear medicine to treat cancerous tumours. Lanreotide, a cyclic oc tapeptide, beta -naphthyl-peptide, with antiproliferative action on human s mall cell lung carcinoma was Re-188 labelled and characterised, and its bio distribution was studied in mice. Molecular modelling indicates that the li pophilic radiopharmaceutical might be an oxo-rhenium (V) penta-coordinated complex. The implanted human cervical tumour of epidermoid origin was posit ive for cytokeratins and Vimentin. Uptake of Re-188-labelled peptide in the implanted tumour in athymic mice was 6.2+/-2.9% and was rapidly cleared vi a the hepatobiliary system. Re-188-beta -naphthyl-peptide might be a potent ial therapeutic agent. (C) 2001 Elsevier Science Inc. All rights reserved.